Provider Guide: Helping Your Patients Save Money on Wegovy

The cost of Wegovy is one of the biggest barriers to long-term obesity treatment success — and it falls on prescribers to help navigate it. This guide walks you through the full landscape of Wegovy affordability tools: manufacturer savings programs, prior authorization strategies, formulary navigation, patient assistance programs, and how services like FindUrMeds can help your patients find both access and better pricing across 15,000+ pharmacy locations nationwide.

---

Why Cost Is a Clinical Issue, Not Just a Financial One

Wegovy (semaglutide 2.4 mg) has demonstrated meaningful, sustained weight loss in clinical trials — but that only matters if your patient can stay on it.

At a list price of approximately $1,300–$1,400 per month, Wegovy is out of reach for a large portion of patients without robust insurance coverage. Even patients with commercial insurance often face high copays, step therapy requirements, or outright exclusions. And for Medicare patients, obesity pharmacotherapy remains largely uncovered thanks to a long-standing statutory exclusion — though that landscape is slowly shifting.

The result: patients who are clinically appropriate candidates are abandoning therapy within the first few months, not because of side effects, but because of cost. That's a problem worth solving proactively at the point of prescribing.

Here's what you can do.

---

Understanding the Full Cost Burden Your Patients Face

Before you can help, it's worth knowing exactly where patients get stuck.

Uninsured patients bear the full list price — often $1,300–$1,400/month — which is simply unworkable for most households on a chronic therapy timeline.

Commercial insurance patients may have coverage, but frequently face:

• High-tier specialty copays ($100–$300+/month)
• Step therapy requirements (requiring documented failure on other agents first)
• Quantity or BMI restrictions
• Annual benefit caps that reset mid-treatment

Medicare Part D patients are in the most difficult position. Federal law has historically prohibited Medicare from covering medications prescribed solely for weight loss, meaning most Part D plans exclude GLP-1s when prescribed for obesity. Patients who also carry a diagnosis of type 2 diabetes may have a clearer path — but even then, coverage is plan-specific.

Medicaid coverage varies significantly by state. Some state Medicaid programs cover Wegovy with prior authorization; others do not cover it at all.

Knowing which category your patient falls into before you write the prescription lets you direct them to the right resources from day one.

---

Novo Nordisk Savings Programs: Start Here for Commercial Patients

For commercially insured patients, Novo Nordisk offers a savings card program that can reduce out-of-pocket costs significantly — in some cases to as low as $0/month for eligible patients, though the actual benefit depends on their insurance plan and current program terms.

A few important caveats to share with patients:

• These savings cards cannot be used with government insurance (Medicare, Medicaid, TRICARE, etc.)
• Eligibility and benefit amounts can change — direct patients to WegovyPro.com or the Novo Nordisk patient support line for current details
• Cards may have monthly or annual caps, so costs can increase once a cap is reached

Tip for your practice: Build a workflow where your MA or care coordinator checks savings card eligibility before or at the same visit you write the prescription. A patient who walks out with both the prescription and the savings card is far more likely to start therapy.

---

The NovoCare Patient Assistance Program

For uninsured or underinsured patients who don't qualify for the commercial savings card, NovoCare is Novo Nordisk's patient assistance program. Eligible patients may be able to receive Wegovy at low or no cost.

Income and insurance criteria apply, and the process can take time — but for patients who are otherwise priced out entirely, it's worth pursuing.

Provide your patients with:

• NovoCare phone: 1-866-310-7549
• Website: novocare.com

Your office may need to complete paperwork as part of the enrollment process, so designating a staff member to own this workflow will reduce friction considerably.

---

Prior Authorization: Fighting for Coverage Efficiently

For patients on commercial insurance who should have coverage but are getting denied or delayed, prior authorization is often the battleground.

Common PA Criteria for Wegovy

Most commercial plans require documentation of:

• BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease)
• Previous attempts at lifestyle modification
• Sometimes: documented failure of other pharmacologic agents (step therapy)

How to Strengthen a PA Submission

• Document comorbidities thoroughly — don't just list obesity. Tie it explicitly to cardiovascular risk, metabolic dysfunction, or other qualifying conditions in your clinical notes.
• Be specific about lifestyle interventions — generic language like "diet and exercise counseling provided" is weaker than "patient enrolled in structured 12-week behavioral intervention with documented 3-5% weight loss, with inadequate response."
• Reference clinical guidelines — cite the 2023 American Association of Clinical Endocrinology (AACE) guidelines or the AHA/ACC/TOS obesity guidelines to support medical necessity.
• Quantify functional impairment — if obesity is affecting mobility, sleep, glycemic control, or cardiovascular risk, say so explicitly.

Appeals

When initial PAs are denied, appeal rates are meaningful. Peer-to-peer review requests — where you speak directly with the plan's medical reviewer — are often more successful than written appeals alone. If your practice has a high volume of GLP-1 prescribing, developing a standard appeal template saves time across patients.

---

Formulary Navigation: Tier Placement and Alternatives

Wegovy is typically placed on a specialty tier when it appears on commercial formularies at all. That tier placement means higher copays and, often, additional utilization management requirements.

A few strategies:

Check the formulary before writing. Tools like formulary lookup on payer portals, or your EHR's integrated benefit checker, can tell you upfront whether Wegovy is covered and at what tier — before your patient hits a wall at the pharmacy counter.

Consider whether Ozempic (semaglutide for type 2 diabetes) is relevant. For patients who carry a type 2 diabetes diagnosis, Ozempic uses the same active ingredient (semaglutide) and may have better formulary placement. This is a prescribing decision that requires clinical judgment and appropriate diagnosis documentation — but it's a legitimate option for qualifying patients, and many plans cover it more readily than Wegovy.

Know the alternatives on formulary. If Wegovy is excluded from a patient's plan entirely, other GLP-1 agonists or weight management medications may have better coverage. For a clinical breakdown of alternatives, see alternatives to Wegovy.

---

Pharmacy Shopping: Price Variation Is Real and Significant

Here's something many prescribers don't realize: the cash price for Wegovy can vary by hundreds of dollars depending on the pharmacy — even for the same dose and quantity.

Large chain pharmacies (CVS, Walgreens, Rite Aid) typically price Wegovy near full list price for cash-pay customers. Warehouse clubs like Costco and Sam's Club often carry meaningfully lower prices for members. Some regional grocers and independent pharmacies may also offer more competitive pricing.

For patients paying out of pocket — even partially — a quick pharmacy price comparison can result in real monthly savings.

GoodRx and manufacturer coupons can sometimes be layered with cash pricing at certain pharmacies, though they cannot be combined with insurance at the same time. Advise patients to check both options.

---

The Compounded Semaglutide Conversation

During recent periods of FDA-shortage designation for Wegovy, compounded semaglutide became widely available through 503A and 503B compounding pharmacies, often at substantially lower price points.

As of mid-2025, the FDA shortage designation has been resolved, which significantly restricts the legal pathway for compounded semaglutide. The regulatory landscape continues to evolve, and compounders are contesting some FDA determinations.

What to tell patients: Compounded semaglutide is not FDA-approved, and product quality, dosing accuracy, and safety are not regulated the same way as brand-name Wegovy. If patients ask, be honest about both the cost appeal and the regulatory and safety uncertainties. This is an area where your clinical judgment matters — and where the situation may continue to change.

---

How FindUrMeds Helps With Both Access and Affordability

Cost isn't the only challenge. Even patients who have coverage or a plan to pay can run into stock shortages — Wegovy has experienced persistent supply constraints, and not every pharmacy carries every dose at any given time. how to help patients find Wegovy in stock

FindUrMeds contacts pharmacies directly on your patient's behalf — across 15,000+ locations including CVS, Walgreens, Rite Aid, Walmart, Kroger, Publix, Costco, and Sam's Club — and identifies where their specific dose is in stock, typically within 24–48 hours.

For your practice, this means fewer callbacks from frustrated patients who can't locate their medication and less administrative time spent on pharmacy tracking. For your patients, it means less time calling around and a clearer path from prescription to dispensing.

A 92% success rate across more than 200 participating healthcare provider relationships makes FindUrMeds a practical tool to have in your patient education toolkit — especially for a medication like Wegovy where both shortage and cost issues can interrupt care.

---

A Practical Checklist: At the Point of Prescribing

When you write a Wegovy prescription, consider walking through this quick checklist:

• Verified insurance coverage and tier placement via formulary lookup
• Initiated or delegated prior authorization if required
• Provided commercial savings card information (for eligible patients)
• Flagged for NovoCare PAP if uninsured/underinsured
• Discussed pharmacy options and price variation for cash-pay patients
• Provided FindUrMeds as a resource if stock availability is a concern
• Documented comorbidities and treatment history in notes for PA support

---

Frequently Asked Questions

Does Medicare cover Wegovy at all?

Not typically for obesity treatment alone. Federal statute has historically excluded medications prescribed solely for weight loss from Medicare Part D coverage. However, if a patient also has type 2 diabetes or cardiovascular disease, coverage pathways may exist for semaglutide products under different indications. Consult the patient's specific plan, and monitor federal legislative developments — this area is evolving.

What's the most effective way to help an uninsured patient access Wegovy?

Start with the NovoCare Patient Assistance Program from Novo Nordisk, which may provide the medication at low or no cost for qualifying patients. For patients who don't qualify, compare cash pricing across pharmacy types (warehouse clubs often have lower prices) and evaluate whether GoodRx or similar discount tools provide meaningful savings. Also consider whether an alternative agent with better cost profile may be clinically appropriate.

How does step therapy affect my Wegovy patients, and can it be appealed?

Step therapy requirements mean patients must document failure on a prior agent before the payer will approve Wegovy. You can sometimes request a step therapy exception if there's a clinical reason the required agent is contraindicated or inappropriate for that patient. Document your rationale carefully and include clinical guidelines to support the exception request.

How is FindUrMeds different from just telling a patient to call pharmacies themselves?

FindUrMeds does the outreach for them — contacting pharmacies directly across a wide network to find their specific prescription in stock. For a medication like Wegovy where certain doses may be limited at any given location, this saves patients significant time and frustration, and it removes a common barrier to actually starting or continuing therapy.

---

Need help finding Wegovy in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.

Find Wegovy Near You →

---

FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.

About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →